Selective inhibition of autoimmune exacerbation while preserving the anti-tumor clinical benefit using IL-6 blockade in a patient with advanced melanoma and Crohn’s disease: a case report

Abstract Background Novel immunotherapies, or checkpoint inhibitors, targeting programmed cell death protein-1 (PD-1) and cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) have significantly improved outcomes for patients with numerous different cancer types. However, owing to their exclusion fro...

詳細記述

書誌詳細

出版年:	Journal of Hematology & Oncology
主要な著者:	Marc Uemura, Van A. Trinh, Cara Haymaker, Natalie Jackson, Dae Won Kim, James P. Allison, Padmanee Sharma, Luis Vence, Chantale Bernatchez, Patrick Hwu, Adi Diab
フォーマット:	論文
言語:	英語
出版事項:	BMC 2016-09-01
主題:	Checkpoint inhibitors PD-1 CTLA-4 Pembrolizumab Tocilizumab Crohn’s disease
オンライン･アクセス:	http://link.springer.com/article/10.1186/s13045-016-0309-7